Discovery of Pyrano[3,4-b]indoles as Potent and Selective HCV NS5B Polymerase Inhibitors
摘要:
A novel series of HCV NS5B RNA-dependent RNA polymerase inhibitors containing a pyrano-[3,4-b]indole scaffold is described leading to the discovery of compound 16, a highly potent and selective inhibitor that is active in the replicon system.
Etodolic acid and related compounds. Chemistry and antiinflammatory actions of some potent di- and trisubstituted 1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acids
作者:Christopher A. Demerson、Leslie G. Humber、Adolph H. Philipp、Rene R. Martel
DOI:10.1021/jm00225a010
日期:1976.3
4-b]indole-1-acetic acids bearing one, or two, substituents on the benzene ring has been synthesized via the acid-catalyzed condensation of a substituted tryptophol with ethyl propionylacetate or ethyl butyrylacetate. Antiinflammatory and ulcerogenic effects were examined and the results show that 1, 8-diethyl-1, 3, 4, 9-tetrahydropyrano[3, 4-b]indole-1-acetic acid (etodolic acid, USAN) is a potent agent, particularly
一系列在苯环上带有一个或两个取代基的37种1-乙基和1-n-丙基-1,3,4,9-四氢吡喃[3,4-b]吲哚-1-乙酸通过取代的色酚与丙酸乙酯或丁酸乙酯的酸催化缩合反应合成。检查了抗炎和促溃疡作用,结果表明1、8-二乙基-1、3、4、9-四氢吡喃并[3,4-b]吲哚-1-乙酸(依托度酸,USAN)是有效的药物,在慢性大鼠炎症模型(佐剂性关节炎模型中,ED50 0.7 + 1-0.1 mg / kg po)特别有效,并且在同一物种中具有相对较低的急性致溃疡性。
[EN] METHOD FOR THE USE OF PYRANOINDOLE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS<br/>[FR] METHODE D'UTILISATION DE DERIVES DU PYRANOINDOLE POUR TRAITER UNE INFECTION PAR LE VIRUS DE L'HEPATITE C
申请人:WYETH CORP
公开号:WO2003099275A1
公开(公告)日:2003-12-04
The invention is directed to methods of treating, preventing, or inhibiting a Hepatitis C viral infection in a mammal comprising containing the mammal with an effective amount of a compound of the formula: Wherein substitutions at R1, R2, R3-R12, and Y are set forth in the specification.
Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus
申请人:Wyeth
公开号:US20040082643A1
公开(公告)日:2004-04-29
The invention is directed to methods of treating, preventing, or inhibiting a Hepatitis C viral infection in a mammal comprising contacting the mammal with an effective amount of a compound of the formula:
1
Wherein substitutions at R
1
, R
2
, R
3
-R
12
, and Y are set forth in the specification.